Google NewsCyclopharm (ASX:CYC): US Technegas Growth Meets a Tougher Rollout Timetable - Kalkine
Cyclopharm (ASX:CYC): US Technegas Growth Meets a Tougher Rollout Timetable Kalkine
CYC
Cyclopharm
Health Care Equipment & Services
Cyclopharm is a global radiopharmaceutical company focused on lung imaging solutions. Their flagship product, Technegas, is used for pulmonary embolism diagnosis and other lung conditions. The company aims to advance nuclear pulmonology imaging through innovation and a commitment to superior patient care.
Short position
short percentage0.00%
reported shorts343
shares on issue125.734M
Cyclopharm (ASX:CYC) has 0.00% of its shares on issue reported as short positions as of 28 Sept 2026, or about 343 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.19% in August 2025. CYC is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Cyclopharm (CYC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineDoes China Endorsement Lift Cyclopharm's Outlook (ASX:CYC)?
Highlights Chinese medical bodies named Technegas their preferred lung ventilation agent. The consensus aims to standardise pulmonary embolism imaging across hospitals. Health care led the local market on a session when financials lagged. Cyclopharm (ASX:CYC) has secured a notable endorsement in China, where multiple leading medical bodies have named its Technegas as the preferred ventilation agent for lung imaging. The announcement came as the Australian market finished a touch lower, with b...
Small CapsCyclopharm’s Technegas Named as Preferred Ventilation Agent for Lung Imaging in China
Cyclopharm’s Technegas unanimously recommended as China’s preferred ventilation agent for lung imaging by seven leading medical bodies.
Cyclopharm (ASX:CYC) Wins Major China Endorsement as Global Support for Technegas Builds - Stocks Down Under
Cyclopharm (ASX:CYC) Wins Major China Endorsement as Global Support for Technegas Builds Stocks Down Under
ASXChinese Consensus Names Technegas Preferred Lung Agent
other announcement
StockheadDr Boreham’s Crucible: Cyclopharm breathes easier after Technegas endorsement
Cyclopharm’s Technegas has won a major international guideline endorsement as the company builds out its long-awaited US rollout. ... Read More The post Dr Boreham’s Crucible: Cyclopharm breathes easier after Technegas endorsement appeared first on Stockhead.
Here's Why We're Watching Cyclopharm's (ASX:CYC) Cash Burn Situation - simplywall.st
Here's Why We're Watching Cyclopharm's (ASX:CYC) Cash Burn Situation simplywall.st
Cyclopharm (ASX:CYC) Drops Sharply - Why This ASX Stock Is Under Pressure - Kalkine
Cyclopharm (ASX:CYC) Drops Sharply - Why This ASX Stock Is Under Pressure Kalkine
Why Is Cyclopharm (ASX:CYC) Stirring Smallcaps?
Highlights Cyclopharm is drawing attention as fresh medical imaging guidance lifting attention to smaller healthcare names. Today's ASX tone is shaped by smallcap healthcare is rewarding evidence over broad promises. The key question is can specialist healthcare names earn attention while the wider sector is fragile. A: ustralia's sharemarket has opened with a firmer pulse, and AFT Pharmaceuticals (ASX:AFP), a regional pharmaceutical company with product development programs, is helping frame...
Why Is Cyclopharm (ASX:CYC) in Health Focus?
Highlights Cyclopharm is drawing attention as Technegas recognition in updated lung imaging guidance. Today's ASX tone is shaped by specialist healthcare names can move when evidence becomes clearer. The key question is whether guideline recognition can support a broader commercial conversation. A: ustralia's sharemarket has opened with a firmer pulse, and AFT Pharmaceuticals (ASX:AFP), a regional pharmaceutical company with product development programs, is helping frame why Cyclopharm matter...
Cyclopharm (ASX:CYC) named preferred agent in first US lung imaging rewrite in 14 years - Stocks Down Under
Cyclopharm (ASX:CYC) named preferred agent in first US lung imaging rewrite in 14 years Stocks Down Under
New US Lung Imaging Guidelines Name Technegas as Preferred A
other announcement
Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61 - Kalkine
Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61 Kalkine
Immediate 11-Site Technegas Rollout at University Hospitals
other announcement
Appointment of Non-Executive Director and Incoming Chair
other announcement
Resignation of Non-Executive Director John Wigglesworth
other announcement
CYC Secures Multi-Site Agreement with Northwestern Medicine
other announcement
Change of Director's Interest Notice - JM
director_dealing announcement
Change of Director's Interest Notice - KB
director_dealing announcement
Change of Director's Interest Notice - JW
director_dealing announcement
Change of Director's Interest Notice - DA
director_dealing announcement
Change of Director's Interest Notice - DH
director_dealing announcement
Technegas US Footprint Expanding Across Four Regions
other announcement
Technegas Approved at the US National Institutes of Health
other announcement